CD274 and non-small cell lung carcinoma: In NSCLC patients previously treated with chemotherapy and anti-PD-1/PD-L1 therapy the disease control rate was 96% and objective response rate (ORR) was 45% (https://cm.eortc.org/cmPortal/Searchable/ENA2020/config/normal#!abstractdetails/0000902150).